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A New Metric for Interventional Cardiology?*Michael E. Farkouh, MD, MSCE xtensive research has been committed toimproving outcomes after coronary percuta-neous intervention (PCI). Over the past 2
decades, there has been a great deal of attention
committed to the study of elevated low-density lipo-
protein (LDL) and blood pressure as major determi-
nants of progression of coronary artery disease
(CAD) (1). But what about blood glucose?
With the advent of the PROSPECT trial, novel
imaging of patients with acute coronary syndrome
(ACS), identiﬁed large plaque burden and thin-cap
ﬁbroatheromas (TCFA) as determinants of non-
culprit lesions that were responsible for subsequent
major adverse cardiovascular events (MACE) (2). The
availability of imaging technology to identify the
percent necrotic core (NC) is at the heart of identi-
fying pathological features of the vulnerable plaque.
In stable CAD, hyperglycemia in the form of chronic
blood sugar elevation with abnormal hemoglobin A1c
is associated with worse outcome after PCI. As a
result, patients are treated for hyperglycemia only
when a diagnosis of diabetes is established by an oral
glucose tolerance test or by a chronic A1c elevation
above 6.5%. Diabetic patients are treated with insulin
when they have a longer duration of diabetes or with
oral hypoglycemic agents or diet when they have a
reduced duration of diabetes. The main problem with
antidiabetic therapies is the side effects, mainly
weight gain, hypoglycemia, and heart failure (3).
In recent years, epidemiological studies have sug-
gested that glycemic variability (GV) may be a marker*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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plaque vulnerability. Glycemic variability as mea-
sured by the mean amplitude of glycemic excur-
sions (MAGE) underscores the vulnerability of a
single patient to develop large excursions of blood
glucose over repeated measurements over a rela-
tively short measure of time. This has been made
possible by the advent of continuous blood glucose
monitoring.
There have been multiple studies that document
that increased GV is associated with worse outcome
both for surrogate and clinical outcome measures
and this has been documented, not only in diabetic,
but also nondiabetic, patients. In type 2 diabetic pa-
tients with and without CAD, GV correlated with
increased brachial artery endothelium-dependent
ﬂow-mediated dilation, increased C-reactive protein
and increased insulin resistance as measured by
homeostatic model assessment–insulin resistance (4).
A positive association of GV with increased carotid
intima-medial thickness in type 2 diabetic patients
has been shown to be independent of hemoglobin A1C
levels (5).
Glycemic variability have also been associated with
worse short-term prognosis for acute myocardial
infarction (MI) after primary PCI (6). In a study of 237
patients with ST-segment elevation MI, a higher
MAGE level was associated with higher peak creatine
kinase-myocardial band (p < 0.01) and, when classi-
ﬁed by terciles, a higher composite rate of MACE
(7.5% vs. 14.0% vs. 22.7%, p ¼ 0.025). Overall, MAGE
was an independent predictor of composite MACE in
ST-segment MI patients undergoing primary PCI. In
acute MI patients, MAGE, along with the inﬂamma-
tory mediators CD-14 and CD-16, has been shown to
be signiﬁcantly and negatively correlated with the
myocardial salvage index (7).
With regard to the question of coronary plaque
vulnerability, Teraguchi et al. (8) studied the impact
of glucose ﬂuctuation on plaque vulnerability in 37
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813acute MI patients undergoing optimal coherence to-
mography. Elevated MAGE levels were more likely in
those patients with documented plaque rupture.SEE PAGE 800In this issue of JACC: Cardiovascular Interven-
tions, Kuroda et al. (9) from Japan reported on an
elegant study in stable coronary artery disease. This
study is important because the research to date on GV
has pertained largely to the ACS population. The
question was whether GV was also a predictor of
plaque vulnerability in patients undergoing elective
PCI. There are a number of important aspects to this
study in addition to its excellent design. First, the
trial has patients under reasonable LDL control. This
is important because we know the importance of LDL
cholesterol in the outcome of patients undergoing PCI
with stable CAD. Second, they were able to identify
new diabetic patients on the basis of an oral glucose
tolerance test. These results are important because
they underscore the fact that one-third of diabetic
patients are unaware of their diagnosis at the time of
PCI.
Their ﬁndings indicate a strong correlation be-
tween increasing MAGE and a higher percent NC,
regardless of diabetic status. Interestingly, a longer
duration of diabetes, which is a strong marker for the
need for insulin therapy, was also associated with a
higher percent NC. Similarly, when performing indi-
vidual plaque analysis, MAGE was the only indepen-
dent predictor of TCFA. As a result, this single study
has brought us greater knowledge of the importance
of GV as a marker of plaque vulnerability as well as
reinforcing the utility of novel imaging strategies to
measure TCFA and percent necrotic core.
Glycemic variability holds promise as a predictor
of future cardiovascular events likely through amechanism of inﬂuencing plaque vulnerability. The
real challenge, however, is demonstrating that
modifying GV can actually improve clinical outcomes.
A number of studies have attempted to address this,
but perhaps the most widely recognized is the
HEART2D (Hyperglycemia and Its Effect After Acute
Myocardial Infarction on Cardiovascular Outcomes in
Patients With Type 2 Diabetes Mellitus) study in the
setting of close to 1,000 acute MI patients and type 2
diabetes (10). Patients were randomized to a strategy
of targeting post-prandial blood glucose versus one
targeting fasting hyperglycemia. The post-prandial
strategy lowered absolute GV by 18% but did not
improve cardiovascular endpoints. Clearly, this study
requires further validation.
In the current evaluation of patients with stable
CAD, much can be learned from the ACS population
when dealing with optimizing medical care. Howev-
er, when it comes to optimizing glycemic control, it
is important that we study these 2 populations
independently and that we have well-powered pro-
spective trials to address the question of GV and
plaque vulnerability. Although it is premature to
adopt MAGE measurements in all our patients un-
dergoing PCI, it may be a proof of concept for
studying novel mechanisms for plaque instability.
It is time for “out of the box” thinking in the man-
agement of stable CAD. The rates of residual risk
post-PCI are too high even for patients prescribed
evidence-based therapies.
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